Deals
Vertex Pharmaceuticals’ acquisition of Crinetics Pharmaceuticals is the largest pickup in the company’s history, according to analysts at BMO Capital Markets.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The Seattle, Wash.-based biotech company says it will raise the funds by offering 15 million shares at $20 to $23 per share.
The 2021 trend of biotech initial public offerings (IPOs) continued this week. Here’s a look.
Last year was a record number of IPOs in the biotech industry, with 81 raising $13.5 billion. With this kind of a start, 2021 may be scorching.
Thermo Fisher Scientific, based in Waltham, Massachusetts, is acquiring Mesa Biotech for about $450 million in cash. There is also an additional $100 million in cash after certain milestones are hit.
Thermo Fisher Scientific announced the completion of Henogen SA, Groupe Novasep SAS’s viral vector manufacturing business in Belgium. The deal was for €725 million in cash.
Many buyers are becoming increasingly interested in buying these promising companies before they go public, as this often makes the purchase more economically feasible.
On January 4, the company announced slightly murky data from its first-in-patients 12-week Phase II proof-of-concept trial of BT-11 for mild to moderate ulcerative colitis.
Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company’s cell-based therapy discovery and development operations.
The deal adds Kymab’s lead asset KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L.
Merck KGaA buys Amptec for mRNA tech and Chimerix acquires Oncoceutics for cancer pipeline.